| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5699874 | Clinical Oncology | 2006 | 6 Pages |
Abstract
These results suggest that the combined modality of conformal HDR brachytherapy and EBRT is a feasible treatment modality with acceptable acute and late toxicities, comparable with those of EBRT alone. It offers an attractive conformal treatment modality with the potential of further dose escalation in the treatment of localised prostate cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Y.S. Chin, J. Bullard, L. Bryant, P. Bownes, P. Ostler, P.J. Hoskin,